Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

  1. Agache, I.
  2. Rocha, C.
  3. Beltran, J.
  4. Song, Y.
  5. Posso, M.
  6. Solà, I.
  7. Alonso-Coello, P.
  8. Akdis, C.
  9. Akdis, M.
  10. Canonica, G.W.
  11. Casale, T.
  12. Chivato, T.
  13. Corren, J.
  14. Del Giacco, S.
  15. Eiwegger, T.
  16. Firinu, D.
  17. Gern, J.E.
  18. Hamelmann, E.
  19. Hanania, N.
  20. Mäkelä, M.
  21. Martín, I.H.
  22. Nair, P.
  23. O'Mahony, L.
  24. Papadopoulos, N.G.
  25. Papi, A.
  26. Park, H.-S.
  27. Pérez de Llano, L.
  28. Quirce, S.
  29. Sastre, J.
  30. Shamji, M.
  31. Schwarze, J.
  32. Canelo-Aybar, C.
  33. Palomares, O.
  34. Jutel, M.
  35. Erakutsi egile guztiak +
Aldizkaria:
Allergy: European Journal of Allergy and Clinical Immunology

ISSN: 1398-9995,  0105-4538

Argitalpen urtea: 2020

Alea: 75

Zenbakia: 5

Orrialdeak: 1043-1057

Mota: Artikulua

DOI: 10.1111/ALL.14235 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus